The healthcare system in the United States is in dire need of reform, and the culprit is none other than the so-called 'Big Medicine' conglomerates. These behemoths, which include insurance companies, pharmacy benefit managers (PBMs), and drug wholesalers, have been driving up healthcare costs and stifling competition, leaving Americans with middling healthcare and the highest medical expenses in the world. The situation is dire, and it's time to take a hard look at the role these entities play in our healthcare system.
One of the most concerning aspects of Big Medicine is the way they control the prescription drug market. The 'big three' PBMs, CVS Caremark, Cigna's Express Scripts, and UnitedHealth Group's Optum Rx, control a staggering 80% of U.S. prescriptions. But that's not all; these companies are also vertically integrated with major insurance conglomerates and pharmacies, giving them even more power over the healthcare landscape. The Federal Trade Commission has found that these PBMs leverage their market power to drive up drug costs and push independent pharmacies out of business, with some pharmacies being paid up to 7,736% more than unaffiliated competitors.
The situation is further complicated by the drug wholesalers, who control 96% of U.S. drug distribution. These companies are also vertically integrated with medical providers, including oncology clinics and other specialty practices with high drug costs. This arrangement creates conflicts of interest, as seen in the case of Cencora, which agreed to pay $1 million to resolve allegations of paying kickbacks to health care providers and medical practice executives.
It's clear that Big Medicine is not just a problem for PBMs and drug wholesalers; it's a systemic issue that affects the entire healthcare system. The pharmaceutical industry abuses patents to keep drug costs high and block competition from more affordable generics, but that doesn't let Big Medicine off the hook. In fact, the situation is even more insidious, as these companies are not just driving up drug costs, but also controlling the healthcare decisions of patients.
The good news is that there is a solution. Lawmakers have finally taken action, passing a spending bill that includes provisions to ban PBMs from pocketing manufacturer rebates, excluding independent pharmacies from their networks in Medicare Part D, and withholding certain pricing information from employer health plan sponsors. But these reforms are just the beginning. Policymakers are now proposing even more aggressive legislation that would extend not just to PBMs but to other 'Big Medicine' middlemen, such as insurance conglomerates and wholesale drug distributors.
One particularly promising development is the Break Up Big Medicine Act, introduced by Senators Elizabeth Warren and Josh Hawley. This bill would prohibit insurers, PBMs, and wholesalers from owning or controlling healthcare providers, including medical practices and pharmacies. In practice, this bill would break up all six of the Big Medicine companies, an effort to lower healthcare costs and promote competition. Research shows that such a ban would reduce drug prices by more than 7%, and public support for this kind of legislation is mounting.
The time for action is now. The healthcare system in the United States is in a state of crisis, and the 'Big Medicine' conglomerates are at the heart of the problem. By breaking up these companies and promoting competition, we can begin to heal the system and provide Americans with the healthcare they deserve. It's time to take a stand and say enough is enough. The future of American healthcare depends on it.
